🔍

TARSONS - Tarsons Products

📊 NSE: TARSONS 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 14:08

📢 Recent Corporate Announcements

Tarsons Products Seeks Shareholder Approval for Independent Director Appointment for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 06 Mar 2026, 03:55 PM

Tarsons Products Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director. The proposed appointment is for a five-year term effective from February 6, 2026, through February 5, 2031. Shareholders can cast their votes via a remote e-voting process that runs from March 7, 2026, to April 6, 2026. This appointment is being proposed as a Special Resolution to comply with SEBI Listing Regulations and the Companies Act.

Appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director for a 5-year tenure.
The proposed term runs from February 6, 2026, to February 5, 2031.
Remote e-voting period is set for 30 days, starting March 7 and ending April 6, 2026.
The cut-off date for determining shareholder voting eligibility was February 27, 2026.
The resolution requires approval as a Special Resolution via postal ballot.

💡 Investors should review the director's credentials in the explanatory statement to ensure the board's composition remains robust. This is a routine governance matter and does not require any change in investment strategy.

Tarsons Products Q3 FY26: Revenue Up 12.8%, Adjusted Cash PAT Surges 38.6% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 05:41 PM

Tarsons Products reported a consolidated revenue of ‑108 crores for Q3 FY26, a 12.8% YoY growth, while adjusted cash PAT rose significantly by 38.6% to ‑31.4 crores. Reported PAT was impacted by higher depreciation of ‑60.6 crores for 9M FY26 following the partial capitalization of the Panchla facility. Management highlighted a revenue potential of over ‑150 crores from the new bioprocess container line at full capacity. With cell culture capex expected to commercialize in Q4 FY26, the company anticipates stronger revenue momentum in FY27.

Consolidated revenue grew 12.8% YoY to ‑108 crores in Q3 FY26.
Adjusted Cash PAT increased by 38.6% YoY to ‑31.4 crores, reflecting strong operational performance.
Standalone EBITDA margin stood at 34.7%, while consolidated EBITDA margin was 29.2%.
New bioprocess container capacity has a potential revenue generation of ‑150+ crores at full utilization.
Depreciation increased to ‑60.6 crores for 9M FY26 due to the ‑600 crore Panchla facility expansion.

💡 Investors should monitor the ramp-up of the Panchla facility and the adoption of new cell culture products in FY27. Focus on Cash PAT and EBITDA as primary metrics while the company navigates high depreciation from its major capex cycle.

Tarsons Products to Meet Institutional Investors on February 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 04:56 PM

Tarsons Products Limited has scheduled an investor and analyst meeting for February 16, 2026, in Mumbai. The event, hosted by Spark Capital, will feature both group and one-on-one meeting formats starting from 10:00 A.M. IST. The company has stated that the discussions will be based strictly on publicly available information, ensuring no unpublished price sensitive information is shared. Such meetings are standard practice for maintaining institutional engagement and transparency.

Meeting scheduled for Monday, February 16, 2026, starting at 10:00 A.M. IST
Event hosted by Spark Capital involving Group and 1x1 meeting formats
In-person meetings to be held in Mumbai with various institutional participants
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 This is a routine investor relations update and requires no immediate action. Investors may look for any subsequent investor presentations or transcripts that might be uploaded to the exchanges following the event.

Tarsons Products Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 08:17 PM

Tarsons Products Limited has officially released the audio recording of its investor conference call held on February 6, 2026. The call addressed the company's financial performance for the third quarter and nine months ended December 31, 2025. This routine disclosure allows investors to hear management's perspective on the latest unaudited financial results. A written transcript of the discussion is expected to be filed with the stock exchanges and uploaded to the company website shortly.

Audio recording for Q3 FY26 earnings call made available on February 6, 2026.
Covers financial performance for the nine-month period ended December 31, 2025.
Link to the recording is hosted on the company's official investor relations page.
Transcript of the discussion will be provided to BSE and NSE in due course.

💡 Investors should listen to the call or review the upcoming transcript to gauge management's commentary on revenue growth and margin sustainability for the remainder of FY26.

Tarsons to Infuse EUR 3M in Singapore Subsidiary and Appoints New Independent Director

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:45 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and loan repayments. The board also announced the appointment of Mr. Vinesh Mohan Kriplani, a seasoned M&A and tax expert from the Poonawalla Group, as an Independent Director for a five-year term. This follows the resignation of Mr. Girish Paman Vanvari from the board and its committees. The capital infusion into the Singapore entity is scheduled to be completed in quarterly tranches by March 2027.

Approved equity infusion of EUR 3 million into Singapore-based subsidiary Tarsons Life Science Pte. Ltd.
Capital infusion to be completed in quarterly tranches on or before March 31, 2027.
Appointed Mr. Vinesh Mohan Kriplani, a veteran with 29+ years of experience in M&A and taxation, as Independent Director.
Mr. Girish Paman Vanvari resigned as Independent Director and Chairperson of Audit and Risk committees.
The Singapore subsidiary reported nil turnover for the financial years 2023-24 and 2024-25.

💡 Investors should monitor the strategic utilization of the EUR 3 million infusion in the Singapore subsidiary, which is currently a non-operating entity. The addition of a high-profile M&A expert to the board is a positive sign for future corporate governance and strategic growth.

Tarsons Q3FY26 Revenue up 13% to ₹108 Cr; Adjusted Cash PAT grows 39% YoY

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 06 Feb 2026, 12:41 PM

Tarsons Products reported a 12.8% YoY growth in consolidated revenue for Q3FY26, reaching ₹107.9 crores. While EBITDA grew by 6.3% to ₹31.5 crores, the bottom line (Adjusted PAT) for 9MFY26 saw a 41.4% decline due to high depreciation and finance costs from new facility capitalizations. However, Adjusted Cash PAT showed robust growth of 38.6% for the quarter, indicating strong underlying cash generation. The company expects its major capacity expansions at Panchla and Amta to be commissioned in Q4 FY26, which should drive future revenue.

Consolidated Q3FY26 Revenue rose 12.8% YoY to ₹107.9 crores.
Adjusted Cash PAT (PAT + Depreciation) grew 38.6% YoY to ₹31.4 crores in Q3FY26.
9MFY26 EBITDA margins improved to 27.7% from 26.3% YoY.
Consolidated 9MFY26 revenue mix stands at 52% Domestic and 48% Overseas.
Final phase of capacity expansion is on track for commissioning in Q4 FY26.

💡 The stock is currently in a high-capex phase where accounting profits are suppressed by depreciation; investors should monitor the revenue scale-up from new plants in FY27.

Tarsons to Infuse EUR 3M in Singapore Subsidiary; Announces Board Leadership Changes

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:39 PM

Tarsons Products Limited has approved an additional equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and loan repayments. The company also announced the resignation of Mr. Girish Paman Vanvari, an Independent Director who chaired the Audit and Risk committees, citing personal commitments. He is replaced by Mr. Vinesh Mohan Kriplani, a seasoned tax and M&A expert with 29 years of experience, including senior roles at Serum Institute and EY. Consequently, the board has reconstituted its Audit, Risk Management, and Nomination & Remuneration committees effective February 6, 2026.

Approved EUR 3 Million equity infusion in Singapore subsidiary Tarsons Life Science Pte. Ltd.
Resignation of Mr. Girish Paman Vanvari as Independent Director and Audit Committee Chairperson.
Appointment of Mr. Vinesh Mohan Kriplani as Additional Independent Director for a 5-year term.
Capital infusion in the subsidiary to be completed in quarterly tranches by March 31, 2027.
Reconstitution of key board committees including Audit, Risk Management, and NRC.

💡 Investors should monitor the strategic utilization of the EUR 3 million infusion in the Singapore entity and observe if the new board composition brings shifts in governance or M&A strategy. The transition appears orderly with a highly qualified replacement for the outgoing director.

Tarsons Products to Infuse EUR 3 Million in Singapore Subsidiary and Appoints New Director

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 06 Feb 2026, 12:34 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund loan repayments and operational expenses. The board also announced the appointment of Mr. Vinesh Mohan Kriplani, a veteran tax and M&A expert with 29 years of experience, as an Independent Director for a five-year term. Simultaneously, Mr. Girish Paman Vanvari has resigned from his position as an Independent Director due to personal commitments. These changes have led to a reconstitution of the company's Audit, Risk Management, and Nomination committees.

Approved EUR 3 million (approx. ₹27 crore) equity infusion in Singapore subsidiary to be completed by March 2027.
Appointment of Mr. Vinesh Mohan Kriplani, former Senior Partner at EY India, as an Additional Independent Director.
Resignation of Mr. Girish Paman Vanvari as Independent Director and Chairperson of the Audit Committee.
Released unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
Reconstitution of Audit, Nomination and Remuneration, and Risk Management Committees effective February 06, 2026.

💡 Investors should review the detailed Q3 FY26 financial results to assess operational performance while monitoring the strategic utility of the Singapore SPV. The addition of a high-profile M&A and tax expert to the board suggests a continued focus on corporate governance and potential international growth.

Tarsons Products Appoints Vinesh Kriplani as Director; Infuses EUR 3M in Singapore Subsidiary

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 06 Feb 2026, 12:31 PM

Tarsons Products Limited has announced a leadership transition with the appointment of Mr. Vinesh Mohan Kriplani, a tax and M&A expert from the Poonawalla Group, as an Independent Director for five years. This follows the resignation of Mr. Girish Paman Vanvari due to personal commitments. Additionally, the board approved a further equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and debt repayment. The capital infusion is expected to be completed in quarterly tranches by March 31, 2027.

Appointment of Mr. Vinesh Mohan Kriplani as Independent Director for a 5-year term effective Feb 6, 2026
Resignation of Mr. Girish Paman Vanvari as Independent Director and Chairperson of Audit & Risk Committees
Approved equity infusion of EUR 3 million in wholly-owned subsidiary Tarsons Life Science Pte. Ltd.
The Singapore subsidiary funding is earmarked for loan repayment and operational expenses
Reconstitution of Audit, Nomination & Remuneration, and Risk Management Committees completed

💡 Investors should monitor if the new director's expertise in M&A and international tax signals a shift toward inorganic growth. Track the performance of the Singapore subsidiary to ensure the EUR 3 million capital infusion generates adequate returns.

Tarsons Products to Infuse EUR 3 Million in Singapore Subsidiary and Appoints New Director

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:27 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to fund debt repayment and operational expenses. The board also approved the financial results for the quarter ended December 31, 2025. In a leadership transition, Mr. Vinesh Mohan Kriplani, a tax and M&A expert from the Poonawalla Group, has been appointed as an Independent Director, while Mr. Girish Paman Vanvari has resigned. The capital infusion is slated for completion in quarterly tranches by March 31, 2027.

Approved EUR 3 million equity infusion into Singapore-based Tarsons Life Science Pte. Ltd.
Capital infusion intended for repayment of existing loans and general corporate purposes, to be completed by March 31, 2027.
Appointment of Mr. Vinesh Mohan Kriplani, a former EY Senior Partner, as an Independent Director for a 5-year term.
Resignation of Mr. Girish Paman Vanvari as Independent Director and Chairperson of the Audit Committee.
Board approved Unaudited Standalone and Consolidated Financial Results for Q3 FY26.

💡 Investors should monitor the detailed Q3 FY26 financial results for operational performance and margin trends. The appointment of a high-profile M&A and tax expert to the board suggests a potential focus on strategic international structuring or future inorganic growth.

Tarsons to Infuse EUR 3 Million in Singapore Subsidiary and Appoints New Independent Director

🔵 WATCH ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:25 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund loan repayments and operational expenses. The board also appointed Mr. Vinesh Mohan Kriplani, a tax and M&A expert from the Poonawalla Group, as an Independent Director for a five-year term. This follows the resignation of Mr. Girish Paman Vanvari from the board due to personal commitments. The company also approved its financial results for the quarter and nine months ended December 31, 2025.

Approved equity infusion of EUR 3 Million into Singapore subsidiary Tarsons Life Science Pte. Ltd. to be completed by March 2027
The Singapore subsidiary is a non-operating SPV that reported nil turnover for FY 2024-25 and FY 2023-24
Appointment of Mr. Vinesh Mohan Kriplani (ex-EY Senior Partner) as Additional Independent Director for a 5-year term
Resignation of Mr. Girish Paman Vanvari as Independent Director and Chairperson of Audit and Risk Management Committees
Board committees, including Audit and Risk Management, have been reconstituted following the leadership changes

💡 Investors should monitor the specific financial performance in the Q3 FY26 results and the strategic purpose of the EUR 3 million infusion into the non-operating Singapore SPV. The addition of a tax and M&A specialist to the board may indicate future strategic restructuring or international expansion plans.

Tarsons Products Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 07:05 PM

Tarsons Products Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all dematerialization and rematerialization requests for the quarter ended December 31, 2025, have been processed. This is a mandatory procedural filing to ensure that electronic shareholding records are accurately maintained and reported to the stock exchanges. The filing demonstrates the company's adherence to standard regulatory timelines.

Compliance certificate submitted for the quarter ended December 31, 2025.
Certificate issued by Registrar and Share Transfer Agent, KFin Technologies Limited.
Confirms that details of dematerialized/rematerialized securities were furnished to BSE and NSE.
Adherence to SEBI (Depositories and Participants) Regulations, 2018 confirmed.

💡 This is a routine administrative filing with no impact on the company's financial health or stock valuation; no action is required.

Tarsons Products Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Dec 2025, 06:50 PM

Tarsons Products Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This routine regulatory action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the Q3 and nine-month financial results for the period ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially declared and disseminated. The specific date for the board meeting to approve these results will be announced in due course.

Trading window for designated persons to close effective Thursday, January 1, 2026.
Closure is in anticipation of Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
The restriction will be lifted 48 hours after the dissemination of the financial results to the exchanges.
The date of the Board meeting to consider the results is yet to be finalized and communicated.

💡 This is a standard regulatory filing with no impact on company fundamentals; investors should monitor for the upcoming Q3 result date for performance updates.

View All TARSONS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 32.4% YoY to INR 392.41 Cr in FY25. Standalone revenue grew 13.3% YoY to INR 314.18 Cr. H1 FY26 standalone revenue grew 4.7% YoY to INR 151.8 Cr.

Geographic Revenue Split

Domestic market remains the primary revenue driver with expanding market share. International operations, specifically the Nerbe acquisition in Germany, contributed INR 80 Cr (approximately 20.4% of consolidated revenue) in FY25.

Profitability Margins

Standalone Gross Margin improved to 72.2% in H1 FY26 from 71.7% YoY. Standalone PAT Margin declined to 6.7% in H1 FY26 from 13.4% YoY due to higher depreciation and finance costs.

EBITDA Margin

Standalone EBITDA Margin improved by 390 bps to 31.9% in H1 FY26. Consolidated EBITDA (excluding forex/other income) was INR 110.73 Cr in FY25.

Capital Expenditure

Invested INR 150 Cr in the Amta facility. The new Panchla facility was capitalized in FY26, leading to accelerated depreciation of INR 37.9 Cr in H1 FY26.

Credit Rating & Borrowing

CARE Ratings reaffirmed the credit rating on June 20, 2025. Consolidated finance costs rose 91.6% YoY to INR 19.39 Cr in FY25 due to expansion-related debt.

⚙️ Operational Drivers

Raw Materials

Plastic resins and granules (polypropylene/polyethylene) used for labware consumables represent the primary raw material cost.

Capacity Expansion

Panchla facility (newly capitalized) and Amta facility (INR 150 Cr investment). Full capacity utilization is expected over the next 3 to 5 years with a ramp-up starting from FY27.

Raw Material Costs

Standalone Cost of Goods Sold (COGS) was INR 42.3 Cr in H1 FY26, representing 27.8% of revenue.

Manufacturing Efficiency

Operating leverage is expected to improve margins as the Panchla facility ramps up from FY27 onwards.

Logistics & Distribution

Distribution costs are being streamlined through centralized fulfillment; specific % of revenue not disclosed.

📈 Strategic Growth

Expected Growth Rate

14.90%

Growth Strategy

Achieving growth through the strategic acquisition of the Nerbe group to penetrate European markets, ramping up the new Panchla facility from FY27 to leverage scale, and launching new plastic labware products to replace traditional glass labware.

Products & Services

Consumables (pipette tips, centrifuge tubes), reusables, and benchtop equipment used in research, academia, and diagnostics.

Brand Portfolio

Tarsons, Nerbe.

New Products/Services

Expansion in high-quality plastic labware consumables designed to replace glass alternatives in research laboratories.

Market Expansion

Deepening presence in European markets via German subsidiaries Nerbe R&D GmbH and Nerbe Plus GmbH.

Market Share & Ranking

Leading plastic labware manufacturing company in India; expanding domestic wallet share.

Strategic Alliances

Acquisition of the Nerbe group (Germany) for approximately INR 98 Cr to enhance global footprint.

🌍 External Factors

Industry Trends

Industry-wide shift from glass to plastic labware consumables driven by research efficiency and safety; market growing due to increased life science investments.

Competitive Landscape

Competition from both established global players and unorganized local manufacturers.

Competitive Moat

Durable advantages include strong brand equity built over decades, manufacturing scale, and ISO 9001/13485 certifications which act as entry barriers.